SABCS 2025 | CompassHER2 pCR: baseline TILs & pCR after THP in HER2+ breast cancer
Sunil Badve, MD, FRCPath, Emory School of Medicine, Atlanta, GA, discusses a secondary analysis of the ECOG-ACRIN EA1181/CompassHER2 pCR trial (NCT04266249) evaluating stromal tumor-infiltrating lymphocytes (TILs) as predictors of pathologic complete response in stage II/III HER2-positive breast cancer treated with taxane, trastuzumab, and pertuzumab (THP). Higher baseline TIL levels were consistently associated with increased pCR rates, including in hormone receptor-positive disease, supporting a key role for immune contexture and the potential use of TILs to inform neoadjuvant treatment optimization. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
